Development and Validation of a UV-Spectrophotometric method for the Estimation of Nintedanib Esylate in Bulk and its Formulation
DOI:
https://doi.org/10.37591/(rrjops).v9i2.121Abstract
The present work represents a UV spectrophotometric method for the estimation of Nintedanib Esylate in pure and its formulation. Methanol was used as a solvent. Nintedanib Esylate exhibit absorption maxima at 391 nm. The developed method obeyed Beer-Lambert’s law in the concentration range of 3-18 µg/ml having a line equation Y = 0.065x + 0.001 with a correlation coefficient of 0.999. There is no interference from any pharmaceutical excipients. The precision of the method was determined by performing the intra-day study and inter-day study. The accuracy of the method was confirmed by recovery studies from capsules at three different levels by standard additions. Results of the analysis were validated statistically and by recovery study. The analytical method was validated for various parameters as per ICH (International Conference on Harmonization) guidelines. The proposed method was found to be simple, rapid, accurate and precise and can be applied for the routine quality control studies for assay of Nintedanib Esylate in pure and its formulation.
Keywords: ICH guidelines, Method validation, Nintedanib Esylate, UV-Spectrophotometric
Cite this Article
Rohan S. Patil, Moreshwar P. Mahajan. Development and Validation of a UV-Spectrophotometric method for the Estimation of Nintedanib Esylate in Bulk and its Formulation. Research and Reviews: A Journal of Pharmaceutical Science. 2018; 9(2): 49–53p
References
Compound summery of Nintedanib Esylate, Pubchem,
https://pubchem.ncbi.nlm.nih.gov/compound/Nintedanib_esylate#section=Top
Francesco Varone, Nintedanib for the treatment of idiopathic pulmonary fibrosis, Expert opinion on pharmacotherapy, 2018, 1465-6566.
Sanjay Popat, Nintedanib plus docetaxcel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis, Future Oncology, 2014, 10.2217/FON.14.290.
ICH Q2 R1 Text on Validation of Analytical Procedures International Conference on Harmonized Tripartite Guideline November 2005.1-17.
Broacher for Ofev capsule, Copyright © 2016, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (3*16) PC-OF-0325-CONS.
Chemistry review on Ofev Capsule, Center for drug evaluation and research, Application no. 205832orig1s000.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
